This commentary highlights the potential need to incorporate neuraminidase components into future influenza vaccines

Estimates of current mid-season flu vaccine effectiveness (VE) in Europe and China range from 32% to 58% overall, with greater protection against influenza B than A, according to three studies published in Eurosurveillance.

The evolution of the antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is impacted by the nature and number of antigenic exposures.

WHO announced them at the meeting on the composition of Influenza Virus Vaccines. These gatherings are held twice a year, bringing together an advisory group of experts from WHO Collaborating Centres and WHO Essential Regulatory Laboratories.

Launched in Brussels on 30 January to drive political momentum for broader vaccine uptake across all stages of life. The group is co-chaired by Croatian MEP Tomislav Sokol and Lithuanian MEP Vytenis Andriukaitis, a former European Commissioner for Health.

Viral variant and host vaccination status impact infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), yet how these factors shift cellular responses in the human nasal mucosa remains uncharacterized.

After surviving Coronavirus Disease 2019 (COVID-19), some people develop symptoms known as post-acute sequelae of COVID-19 (PASC). PASC is an emerging phenomenon yet to be fully understood, and identifying risk factors has been challenging.

Tremendously exciting times and possibly underestimating the enormity of its impact. These are some of the comments we hear when experts share their insights on the recently available RSV vaccines.